Download
Kraut-et-al_2013_Comorbidities in ADHD children.pdf 277,92KB
WeightNameValue
1000 Titel
  • Comorbidities in ADHD children treated with methylphenidate: a database study
1000 Autor/in
  1. Kraut, Angela A. |
  2. Langner, Ingo |
  3. Lindemann, Christina |
  4. Banaschewski, Tobias |
  5. Petermann, Ulrike |
  6. Petermann, Franz |
  7. Mikolajczyk, Rafael |
  8. Garbe, Edeltraut |
1000 Erscheinungsjahr 2013
1000 LeibnizOpen
1000 Art der Datei
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2013-01-07
1000 Erschienen in
1000 Quellenangabe
  • 13:11
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2013
1000 Lizenz
1000 Verlagsversion
  • http://dx.doi.org/10.1186/1471-244X-13-11 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544568/ |
1000 Ergänzendes Material
  • https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-11#Declarations |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users compared to a control group without ADHD and ADHD medication. METHODS: We used health care data for the years 2004 to 2006 from the German Pharmacoepidemiological Research Database (GePaRD) which includes about 18% of the German population. MPH treatment prevalence and incidence was assessed based on at least one MPH prescription in the given year. In MPH users, the prevalence of psychiatric and other comorbidities was assessed in the quarter of the first MPH prescription and the three preceding quarters, whereas in controls it was assessed in the earliest four quarters of continuous insurance time starting at 01.01.2004 or the start of insurance if this was later. Differences in the presence of comorbid diagnoses between MPH users and controls were tested by logistic regression. RESULTS: In 2005, 1.5% of all children and adolescents aged 3 to 17 years (2.3% of males and 0.6% of females) received MPH in Germany. The proportion of children with a record of a psychiatric comorbidity in any of the nine ICD categories of diagnoses was substantially higher in new MPH users (83%) compared to controls (20%). Cerebro- and cardiovascular comorbidities were rare in general. Still, among new MPH users, 2% of males and females had a diagnosis of a pre-existing cardiovascular disorder but only 1.2% of controls. CONCLUSIONS: Besides MPH treatment prevalence we first publish age-specific incidence rates for Germany. A high proportion of children who were started on MPH had a record of a psychiatric comorbidity preceding the first prescription. Cerebro- and cardiovascular conditions were rare in the studied age range, but still higher among children who received MPH than in the control group. Results show that in a substantial subgroup of patients, comorbidities require a thorough weighting of possible risks of MPH medication against the risks of untreated ADHD.
1000 Sacherschließung
lokal Oppositional Defiant Disorder
lokal Atomoxetine
lokal Psychiatric Comorbidity
lokal Treatment Prevalence
lokal European Medicine Agency
1000 Fachgruppe
  1. Medizin |
  2. Gesundheitswesen |
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/S3JhdXQsIEFuZ2VsYSBBLg==|https://frl.publisso.de/adhoc/creator/TGFuZ25lciwgSW5nbw==|https://frl.publisso.de/adhoc/creator/TGluZGVtYW5uLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/creator/QmFuYXNjaGV3c2tpLCBUb2JpYXM=|https://frl.publisso.de/adhoc/creator/UGV0ZXJtYW5uLCBVbHJpa2U=|https://frl.publisso.de/adhoc/creator/UGV0ZXJtYW5uLCBGcmFueg==|http://orcid.org/0000-0003-1271-7204|https://frl.publisso.de/adhoc/creator/R2FyYmUsIEVkZWx0cmF1dA==
1000 Label
1000 Förderer
  1. German Federal Ministry of Education and Research |
1000 Fördernummer
  1. 01ER0817
1000 Förderprogramm
  1. German Population Based Long Term Follow-Up of ADHD (GEPOLO-ADHD)
1000 Dateien
  1. Comorbidities in ADHD children treated with methylphenidate: a database study
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer German Federal Ministry of Education and Research |
    1000 Förderprogramm German Population Based Long Term Follow-Up of ADHD (GEPOLO-ADHD)
    1000 Fördernummer 01ER0817
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6407384.rdf
1000 Erstellt am 2018-04-03T11:06:52.303+0200
1000 Erstellt von 266
1000 beschreibt frl:6407384
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Thu Jan 30 21:24:39 CET 2020
1000 Objekt bearb. Fri Apr 06 15:27:17 CEST 2018
1000 Vgl. frl:6407384
1000 Oai Id
  1. oai:frl.publisso.de:frl:6407384 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source